Treatment of Chronic Hepatitis C in Special Populations - PubMed (original) (raw)

Review

. 2015 Dec;44(4):883-900.

doi: 10.1016/j.gtc.2015.06.002. Epub 2015 Aug 8.

Affiliations

Review

Treatment of Chronic Hepatitis C in Special Populations

Chalermrat Bunchorntavakul et al. Gastroenterol Clin North Am. 2015 Dec.

Abstract

The management of hepatitis C virus (HCV) infection in special populations is challenging. The efficacy and safety data of the currently approved all-oral direct-acting antiviral combinations, including sofosbuvir, ledipasvir, daclatasvir, paritaprevir/ritonavir/ombitasvir plus dasabuvir (3D), and ribavirin, is compelling for use in special HCV populations, as has recently been recommended by expert guidelines. The treatment regimens and sustained virological response rates for special populations are nearly similar to those of the general HCV population. Sofosbuvir is not recommended in patients with severe renal impairment, and simeprevir and 3D regimen are not recommended for those with decompensated liver disease.

Keywords: Chronic kidney disease; Decompensated cirrhosis; HIV coinfection; Hepatitis C virus; Liver transplantation; Treatment.

Copyright © 2015 Elsevier Inc. All rights reserved.

PubMed Disclaimer

Publication types

MeSH terms

Substances

LinkOut - more resources